Recently, iron succinate active pharmaceutical ingredient (API) and empagliflozin API of Xuancheng Minnohua Pharmaceutical Co., Ltd. (hereinafter referred to as "Xuancheng Minnohua"), a wholly-owned subsidiary of Ningbo Minnohua Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), have both passed the technical review by the Center for Drug Evaluation of the National Medical Products Administration (hereinafter referred to as the "CDE"). The Company has received the Approval Notice for the Marketing Application of Chemical Active Pharmaceutical Ingredients issued by the National Medical Products Administration (NMPA). The registration numbers of the two APIs have been updated to Status A as displayed on the CDE Publicity Platform for Registration Information of APIs, Pharmaceutical Excipients and Pharmaceutical Packaging Materials. We hereby announce the relevant information as follows:
I. Main Content of the Registration Information
(I) Ferrous Succinate
Registration Number: Y20220000178Product Name: Ferrous SuccinateManufacturer: Xuancheng Minnohua Pharmaceutical Co., Ltd.Manufacturer Address: No. 9 Meizigang Road, Xuancheng High-tech Industrial Development Zone, Anhui ProvinceProduct Origin: Domestic ProductionPackaging Specifications: 5kg/bag, 10kg/bag, 15kg/bag, 20kg/bag, 25kg/bagReview and Approval Result: A (API Approved for Use in Marketed Pharmaceutical Preparations)
(II) Empagliflozin
Registration Number: Y20220000587Product Name: EmpagliflozinManufacturer: Xuancheng Minnohua Pharmaceutical Co., Ltd.Manufacturer Address: No. 9 Meizigang Road, Xuancheng High-tech Industrial Development Zone, Anhui ProvinceProduct Origin: Domestic ProductionPackaging Specifications: 5kg/bag, 10kg/bag, 15kg/bag, 20kg/bag, 25kg/bagReview and Approval Result: A (API Approved for Use in Marketed Pharmaceutical Preparations)
II. Indications, Pharmacological Effects and Mechanism of Action
Ferrous Succinate Tablets
Indications: For the prevention and treatment of iron deficiency anemia.Pharmacological Effects and Mechanism of Action: Iron is an essential component of hemoglobin in red blood cells. In cases of iron deficiency, the synthesis of hemoglobin in red blood cells is reduced, leading to microcytosis and impaired oxygen-carrying capacity, which results in iron deficiency anemia. Oral administration of this product replenishes iron and corrects iron deficiency anemia.
Empagliflozin Tablets
Indications: For the treatment of type 2 diabetes mellitus.Pharmacological Effects and Mechanism of Action: Sodium-glucose cotransporter 2 (SGLT-2) is the major transporter responsible for the reabsorption of glucose from glomerular filtrate into the systemic circulation. Empagliflozin, as an SGLT-2 inhibitor, reduces renal glucose reabsorption, lowers the renal glucose threshold, and promotes urinary glucose excretion. In addition, empagliflozin decreases sodium reabsorption and increases sodium delivery to the distal tubule, which may exert effects on several physiological functions including, but not limited to, enhancing tubuloglomerular feedback, reducing intraglomerular pressure, lowering cardiac preload and afterload, and down-regulating sympathetic nerve activity.












